{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T10:47:30Z","timestamp":1776682050202,"version":"3.51.2"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chemoimmunotherapy that utilizes the immunomodulatory effect of chemotherapeutics has shown great promise for treating poorly immunogenic solid tumors. However, there remains a significant room for improving the synergy between chemotherapy and immunotherapy, including the efficient, concurrent delivery of chemotherapeutics and immunomodulators into tumors. Here, we report the use of metabolic glycan labeling to facilitate cancer-targeted delivery of liposomal chemoimmunotherapy. 4T1 triple-negative breast cancer cells can be metabolically labeled with azido groups for subsequently targeted conjugation of dibenzocycoloctyne (DBCO)-bearing liposomes loaded with doxorubicin and imiquimod (R837) adjuvant <jats:italic>via<\/jats:italic> efficient click chemistry. The encased doxorubicin can induce the immunogenic death of cancer cells and upregulate the expression of CD47 and calreticulin on the surface of cancer cells, while R837 can activate dendritic cells for enhanced processing and presentation of tumor antigens. Targeted delivery of liposomes encapsulating doxorubicin and R837 to 4T1 tumors, enabled by metabolic glycan labeling and click chemistry, showed the promise to reshape the immunosuppressive tumor microenvironment of solid tumors. This cancer-targetable liposomal chemoimmunotherapy could provide a new approach to improving conventional chemotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1010021","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T17:28:56Z","timestamp":1666200536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Targeted delivery of liposomal chemoimmunotherapy for cancer treatment"],"prefix":"10.3389","volume":"13","author":[{"given":"Yusheng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joonsu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Bo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rimsha","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.342.6165.1432","article-title":"Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy\u2013revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat Rev Drug Discovery"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.canlet.2018.08.028","article-title":"Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-22407-6","article-title":"Co-Delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19540-z","article-title":"Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"119659","DOI":"10.1016\/j.biomaterials.2019.119659","article-title":"Dual fluorescence imaging-guided programmed delivery of doxorubicin and CpG nanoparticles to modulate tumor microenvironment for effective chemo-immunotherapy","volume":"230","author":"Dong","year":"2020","journal-title":"Biomaterials"},{"key":"B12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrc1613","article-title":"Immunotherapy and chemotherapy\u2013a practical partnership","volume":"5","author":"Lake","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B13","article-title":"Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors","volume":"63","author":"Nowak","year":"2003","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40820-020-00482-6","article-title":"A review on nano-based drug delivery system for cancer chemoimmunotherapy","volume":"12","author":"Mu","year":"2020","journal-title":"Nanomicro Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba5628","article-title":"Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy","volume":"6","author":"Ringgaard","year":"2020","journal-title":"Sci Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.9b04094","article-title":"Synthetic immunogenic cell death mediated by intracellular delivery of STING agonist nanoshells enhances anticancer chemo-immunotherapy","volume":"20","author":"Chattopadhyay","year":"2020","journal-title":"Nano Lett"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2106350","DOI":"10.1002\/adma.202106350","article-title":"Dual-targeted lipid nanotherapeutic boost for chemo-immunotherapy of cancer","volume":"34","author":"Yong","year":"2022","journal-title":"Adv Mater"},{"key":"B19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.addr.2016.05.009","article-title":"Tumor-targeting peptides from combinatorial libraries","volume":"110","author":"Liu","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.3.3.311","article-title":"Nanoparticle\u2013aptamer bioconjugates for cancer targeting","volume":"3","author":"Farokhzad","year":"2006","journal-title":"Expert Opin Drug Deliv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2297","article-title":"Selective in vivo metabolic cell-labeling-mediated cancer targeting","volume":"13","author":"Wang","year":"2017","journal-title":"Nat Chem Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2021.07.009","article-title":"Extracellular matrix-based cancer targeting","volume":"27","author":"Karamanos","year":"2021","journal-title":"Trends Mol Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","article-title":"Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting","volume":"278","author":"Gialeli","year":"2011","journal-title":"FEBS J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.gendis.2014.12.002","article-title":"Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas","volume":"2","author":"Cathcart","year":"2015","journal-title":"Genes Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: Strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv Drug Deliv Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0168-3659(01)00315-7","article-title":"Tumor targeting using anti-her2 immunoliposomes","volume":"74","author":"Park","year":"2001","journal-title":"J Control Release"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202110305","article-title":"Optimal physicochemical properties of antibody\u2013nanoparticle conjugates for improved tumor targeting","volume":"34","author":"Mittelheisser","year":"2022","journal-title":"Adv Mater"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-12998-6","article-title":"Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies","volume":"10","author":"Medina-Echeverz","year":"2019","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms13193","article-title":"Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy","volume":"7","author":"Chen","year":"2016","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"119795","DOI":"10.1016\/j.biomaterials.2020.119795","article-title":"Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy","volume":"235","author":"Zhou","year":"2020","journal-title":"Biomaterials"},{"key":"B31","doi-asserted-by":"publisher","first-page":"119983","DOI":"10.1016\/j.biomaterials.2020.119983","article-title":"Site-specific MOF-based immunotherapeutic nanoplatforms via synergistic tumor cells-targeted treatment and dendritic cells-targeted immunomodulation","volume":"245","author":"Zhang","year":"2020","journal-title":"Biomaterials"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nature02791","article-title":"Chemical remodelling of cell surfaces in living animals","volume":"430","author":"Prescher","year":"2004","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1038\/nprot.2007.422","article-title":"Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via staudinger ligation","volume":"2","author":"Laughlin","year":"2007","journal-title":"Nat Protoc"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.05.007","article-title":"Recyclable cell-surface chemical tags for repetitive cancer targeting","volume":"347","author":"Bhatta","year":"2022","journal-title":"J Control Release"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-020-0680-1","article-title":"Metabolic labeling and targeted modulation of dendritic cells","volume":"19","author":"Wang","year":"2020","journal-title":"Nat Mater"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41557-020-00587-w","article-title":"Metabolic glycan labelling for cancer-targeted therapy","volume":"12","author":"Wang","year":"2020","journal-title":"Nat Chem"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/anie.201509601","article-title":"Targeted ultrasound-assisted cancer-selective chemical labeling and subsequent cancer imaging using click chemistry","volume":"55","author":"Wang","year":"2016","journal-title":"Angew Chem Int Ed"},{"key":"B38","doi-asserted-by":"publisher","first-page":"119305","DOI":"10.1016\/j.biomaterials.2019.119305","article-title":"In vivo cancer targeting via glycopolyester nanoparticle mediated metabolic cell labeling followed by click reaction","volume":"218","author":"Wang","year":"2019","journal-title":"Biomaterials"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911116107","article-title":"Copper-free click chemistry in living animals","volume":"107","author":"Chang","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1516524113","article-title":"In vivo metabolic labeling of sialoglycans in the mouse brain by using a liposome-assisted bioorthogonal reporter strategy","volume":"113","author":"Xie","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0707090104","article-title":"Copper-free click chemistry for dynamic in vivo imaging","volume":"104","author":"Baskin","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/ange.201206703","article-title":"Bioorthogonal copper-free click chemistry in vivo for tumor-targeted delivery of nanoparticles","volume":"124","author":"Koo","year":"2012","journal-title":"Angewandte Chem"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022769118","article-title":"Cell membrane\u2013camouflaged liposomes for tumor cell\u2013selective glycans engineering and imaging in vivo","author":"Liu","year":"2021"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402201","article-title":"Calreticulin exposure is required for the immunogenicity of \u03b3-irradiation and UVC light-induced apoptosis","volume":"14","author":"Obeid","year":"2007","journal-title":"Cell Death Differ"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: The calreticulin exposure PathwayThe calreticulin exposure pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2011.497","article-title":"A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death","volume":"31","author":"Garg","year":"2012","journal-title":"EMBO J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1805888","DOI":"10.1002\/adma.201805888","article-title":"Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade","volume":"31","author":"Zhou","year":"2019","journal-title":"Adv Mater"},{"key":"B48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1010021\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T17:28:59Z","timestamp":1666200539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1010021\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2022.1010021"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1010021","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"article-number":"1010021"}}